Ledipasvir/sofosbuvir
NS5B (RNA polymerase) inhibitor | |
Clinical data | |
---|---|
Trade names | Harvoni, Hepcinat-LP, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614051 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
JSmol) | |
| |
|
Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat
It is generally well tolerated.
Ledipasvir/sofosbuvir was approved for medical use in the United States, in the European Union, and in Canada in 2014.[8][11][7][12][13] It is on the World Health Organization's List of Essential Medicines.[14]
Medical uses
Cure rates are 94% to 99% in people infected with genotype 1 (46% of HCV cases).[15] It has also been evaluated for the treatment of infection with other hepatitis C genotypes, and has shown promising results in genotypes 3 and 4 (making up 30% and less than 22% of HCV cases respectively).[9][6][16][15]
Resistance
NS5A mutations
Multiple mutations of HCV replicons are necessary to cause a significant effect in resistance due to multiple mechanisms of action.[17] In general, HCV genotype 1a is less resistant to mutation than genotype 1b.[18]
For genotype 1b a single amino acid substitution (e.g. L31V) in the replicon had less than a 100 fold increase in resistance to the ledipasvir in Harvoni, while a two amino acid substitution had over a 1000 fold increase in resistance.[18][19] Genotype 1a had a similar but more substantial increase in resistance with each respective increase in amino acid substitution with resistance associated substitutions at K24R, M28T/V, Q30R/H/K/L, L31M, and or Y93H/N.[6]
NS5A polymorphisms also have an effect on viral resistance with the most common resistance-associated amino acid substitutions detected at Q30R, Y93H or N, and L31M in patients with a rapid virological response (RVR).[6] The specific baseline NS5A resistance-associated polymorphisms observed in clinical trials were M28T/V, Q30H, Q30R, L31M, H58P, Y93H, and Y93N in genotype 1a and L28M, A92T, and Y93H in genotype 1b.[6] Patients with multiple baseline NS5A polymorphisms tend to have higher relapse rates when using ledipasvir/sofosbuvir.[6] The difference in relapse rates between treatment naive and treatment experience groups with baseline NS5A polymorphisms ranges from 1% after a 12-week regimen and 0% after a 24-week regimen respectively.[18][6]
NS5B mutations
A single amino acid substitution S282T contributes to viral resistance and decreases the activity of sofosbuvir in ledipasvir/sofosbuvir by approximately 2 to 18 fold.[18][20]
Cross resistance
No cross resistance was seen in the combination of ledipasvir and sofosbuvir in ION phase 1,2 and, 3 clinical trials as ledipasvir was fully active against sofosbuvir-resistance-associated substitutions and vice versa.[6][21]
Side effects
More than 10% of people taking ledipasvir/sofosbuvir have headaches or fatigue; rashes, nausea, diarrhea, and insomnia occur in between 1% and 10% of people taking it.[6][5]
More severe reactions are connected with allergic reactions to the medications and cardiovascular problems. Harvoni side effects are considered relatively mild compared to older interferon-based treatment.[citation needed]
Ledipasvir/sofosbuvir could cause hepatitis B re-activation in people co-infected with hepatitis B and C viruses. The European Medicines Agency recommended screening all people for hepatitis B before starting ledipasvir/sofosbuvir for hepatitis C in order to minimize the risk of hepatitis B reactivation.[22]
Drug interactions
Ledipasvir/sofosbuvir is a substrate for the drug transporters
Patients are also advised to stay away from
Ledipasvir/sofosbuvir should additionally be avoided when taking amiodarone or other drugs that lower heart rate; there is a serious risk of the heart slowing or stopping when ledipasvir/sofosbuvir is used with such drugs.[6][5]
Mechanisms of action
The most commonly associated mechanism associated with ledipasvir/sofosbuvir is the
NS5A and NS5B inhibitors in combination have a synergistic effect.[27]
Pharmacokinetics
Sofosbuvir is absorbed fast in the plasma with a
Ledipasvir has a maximum concentration at 4 to 4.5 hours after ingestion and is not affected by macronutrients.
Elimination
The
Substance | ng/mL |
---|---|
Ledipasvir | 323 |
Sofosbuvir | 618 |
GS-331007 | 707 |
Note: The maximum concentration is 32% higher in healthy individuals than those infected with Hepatitis C.[6]
Substance | ng*hr/mL |
---|---|
Ledipasvir | 7290 |
Sofosbuvir | 1320 |
GS-33107 | 12,000 |
Note: The maximum concentration is 24% higher in healthy individuals than those infected with Hepatitis C.[6]
Blood detection
An analytical method based on LC tandem MS has been developed for the simultaneous extraction and determination of ledipasvir/sofosbuvir in human plasma using antiviral daclatasvir as an internal standard. Average extraction recoveries for sofosbuvir and ledipasvir were 91.61% and 88.93% respectively.[31]
Society and culture
One manufacturer is Gilead Sciences.[8]
References
- ^ a b "Ledipasvir / sofosbuvir (Harvoni) Use During Pregnancy". Drugs.com. 28 October 2019. Retrieved 17 March 2020.
- ^ "AusPAR: Ledipasvir / Sofosbuvir". Therapeutic Goods Administration (TGA). 29 October 2015. Retrieved 29 August 2020.
- ^ "AusPAR: Sofosbuvir / Ledipasvir". Therapeutic Goods Administration (TGA). 16 November 2017. Retrieved 29 August 2020.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ a b c "Harvoni 90 mg/400 mg film-coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. December 2016. Archived from the original on 27 October 2016. Retrieved 4 February 2017.
- ^ a b c d e f g h i j k l m n o p "Harvoni- ledipasvir and sofosbuvir tablet, film coated Harvoni- ledipasvir and sofosbuvir tablet, film coated Harvoni- ledipasvir and sofosbuvir pellet". DailyMed. 16 March 2020. Retrieved 29 August 2020.
- ^ a b "Harvoni EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 29 August 2020.
- ^ a b c d e f g h "Ledipasvir and Sofosbuvir". The American Society of Health-System Pharmacists. Archived from the original on 25 December 2016. Retrieved 8 December 2016.
- ^ S2CID 31943736.
- ISSN 0512-3054. WHO technical report series;994.
- ^ "Drug Approval Package:Harvoni (ledipasvir and sofosbuvir) Tablets NDA 205834". U.S. Food and Drug Administration (FDA). 3 November 2014. Retrieved 29 August 2020.
"APPLICATION NUMBER: 205834Orig1s000" (PDF) (Summary Review). Center for Drug Evaluation and Research. - ^ "Notice of Compliance (NOC) online query". 25 August 2010.
- ^ "Health Canada Issues Notice of Compliance for Gilead's Harvoni (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C" (Press release). Gilead Sciences, Inc. 16 October 2014. Retrieved 29 August 2020 – via Business Wire.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ PMID 25069599.
- from the original on 5 November 2017.
- PMID 25384189.
- ^ PMID 25859119.
- PMID 23896281.
- PMID 23199507.
- ^ "Harvoni Presribing Information" (PDF). Gilead Sciences. March 2020. Retrieved 2018-02-21.
- ^ "Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 February 2020.
- ^ "Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals". www.natap.org. Retrieved 2018-02-22.
- ^ "Impact of Food and Antacids on Levels of Ledipasvir and Sofosbuvir". www.natap.org. Retrieved 2018-02-22.
- PMID 11481452.
- PMID 30992888.
- PMID 23567084.
- ^ "Sofosbuvir". www.drugbank.ca. Retrieved 2018-03-23.
- PMID 26405313.
- ^ "Pharmacology: Basic Pharmacology, ANS, Endocrine". www.kumc.edu. Archived from the original on 2018-01-15. Retrieved 2018-03-23.
- PMID 27480956.
External links
- "Ledipasvir mixture with sofosbuvir". Drug Information Portal. U.S. National Library of Medicine.